ClinicalTrials.gg
TerminatedNCT05903274Updated Feb 27, 2025

JSP191 (briquilimab) in Subjects with LR-MDS

A Phase 1 interventional study of JSP191 in Lower-risk Myelodysplastic Syndrome, sponsored by Jasper Therapeutics, Inc.. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-27.

Sponsored by Jasper Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was terminated due to a lack of improvement in clinical efficacy outcomes.

From the registry’s dates

  • Primary completion was Oct 2024, 2 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies in Cytopenia with a site in United States — 17 open to participants now, 22 under way, 2 of them phase 3. Cytopenia · United States.

Enrollment
27th of 32
6 · median 33
Started
2023
with 2 others
Phase 1
10 of 51
2 open now
Registered
41st of 51
by date

Among the 51 studies in Cytopenia with a site in United States, this one is the 27th largest by enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2023, is one of 10 in phase 1, and was the 41st registered.

Cytopenia

81 studies on the registry are indexed under Cytopenia; 25 are open to participants now.

Browse Cytopenia studies →

Open to participants now

17 of the 51 studies in Cytopenia with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Cytopenia studies recruiting now, 17 (85%) set no upper age limit and 1 (5%) stops at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Cytopenia with a site in United States, or all of them as a file.
02

Study summary

A Phase 1 study in subjects with LR-MDS to assess the safety and tolerability of JSP191 as a second-line therapy.

Read the detailed description

An open-label, single-arm, dose-escalation study designed to determine the potential safety, efficacy, maximum tolerated dose (MTD) or optimal biologic dose (OBD), and recommended phase 2 dose (RP2D) of JSP191 (briquilimab) monotherapy for LR-MDS subjects with documented cytopenia (red blood cell-transfusion dependent, thrombocytopenia, and/or neutropenia).

03

Conditions studied

  • Lower-risk Myelodysplastic Syndrome

Browse trials for

Keywords

  • LR-MDS
  • cytopenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • MDS with IPSS-R very low, low, or intermediate risk features
  • Symptomatic cytopenias
  • Women of (WOCBP) must agree to use an oral or implanted , a double-barrier method of birth control, or an intrauterine device upon enrollment and through 3 months after receiving the last dose of JSP191
  • Women not of childbearing potential must be (no menstrual period for a minimum of 12 months) or surgically sterilized and have a negative serum pregnancy test upon study entry
  • Male subjects must be surgically sterile or willing to use contraception upon enrollment and through 3 months after receiving the last dose of JSP191
  • Must be willing and able to provide

Exclusion criteria

Exclusion Criteria:

  • Anemia secondary to iron deficiency, vitamin B12 deficiency, or folate deficiency
  • Prior or autologous stem cell transplant
  • Known history of (HIV) (no laboratory testing is required), or active infection with or
  • Pregnant women or women who are nursing and do not wish to discontinue breastfeeding
  • Any other medical condition that, in the opinion of the Investigator, could pose a significant safety risk to the subject or jeopardize the integrity of the study
  • Subjects who, in the opinion of the Investigator, may not be able to comply with the requirements of the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    JSP191

    This study will explore up to 5 ascending dose levels (Cohorts 1, 2, 3, 4, and 5) and subjects will receive JSP191 on Day 1 on each 8-week cycle for 4 consecutive cycles.

    Drug: JSP191

Interventions

  • DrugJSP191

    Subjects will receive intravenous JSP191

    Also known as: JSP191 (Briquilimab)

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of JSP191

    Assessed by the frequency, duration, and severity of adverse events

    Time frame: 32 weeks

07

Study locations

2 sites
  • Memorial Healthcare System
    Hollywood, Florida 33021, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Oct 2024, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2023
First posted
Jun 15, 2023
StartActual
Jun 19, 2023
Primary completionActual
Oct 21, 2024
CompletionActual
Oct 21, 2024
Last update
Feb 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05903274
Lead sponsor
Jasper Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 15, 2023
Start date
Jun 19, 2023
Primary completion
Oct 21, 2024
Completion
Oct 21, 2024
Last update
Feb 27, 2025

Study contacts

Medical Director
study director · Jasper Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Briquilimab

Start the discussion